Reports Q4 revenue $306.3M, consensus $310.21M. “CARVYKTI continued to build on its leadership in multiple myeloma CAR-T in 2025, as we reached more than 10,000 patients treated and achieved franchise profitability,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech (LEGN). “With expanding capacity and ongoing efforts to broaden adoption, including in the community setting, we are focused on executing against the opportunities ahead while extending our innovation leadership across in vivo and allogeneic programs.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech selloff brings favorable risk/reward, says Deutsche Bank
- LEGN Upcoming Earnings Report: What to Expect?
- Legend Biotech: Undervalued BCMA CAR-T Leader with Lower Commercial Risk and DCF-Supported Upside to $50 Target
- Legend Biotech rises 16.6%
- Legend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn